-
Vemurafenib (INN), sold
under the
brand name Zelboraf, is a
medication used for the
treatment of late-stage melanoma. It is an
inhibitor of the B-Raf...
- developed. Two of
these drugs,
vemurafenib and
dabrafenib are
approved by FDA for
treatment of late-stage melanoma.
Vemurafenib was the
first approved drug...
- anti-cancer
medication used in
combination with
vemurafenib (Zelboraf)
alone or with both
vemurafenib and
atezolizumab (Tecentriq) to
treat melanoma....
-
Etoposide Teniposide Tafluposide Bortezomib Erlotinib Gefitinib Imatinib Vemurafenib Vismodegib Azacitidine Azathioprine Capecitabine Cytarabine Doxifluridine...
- and
vemurafenib 720 mg
orally twice daily, or
placebo in
combination with
cobimetinib 60 mg
orally once
daily (21 days on/7 days off) and
vemurafenib 960 mg...
- [citation needed]
There are two FDA-approved
targeted drugs to
treat ECD.
Vemurafenib, an oral
agent approved in 2019,
targets the BRAF protein. It was approved...
-
agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as
vemurafenib and dabrafenib; and a MEK
inhibitor trametinib. When
arising in the nailbed...
-
Hyperkeratosis can also be
caused by B-Raf
inhibitor drugs such as
Vemurafenib and Dabrafenib. It can be
treated with urea-containing creams, which...
- plus
encorafenib 450 mg once daily,
encorafenib 300 mg once daily, or
vemurafenib 960 mg
twice daily.
Treatment continued until disease progression or...
-
Cotreatment with CYP1A2
inhibitors like ciprofloxacin,
fluvoxamine or
vemurafenib can
reduce chlorpromazine clearance and
hence increase exposure and potentially...
